Unicycive Therapeutics, Inc. (UNCY)

NCM – Цена в реальном времени. Валюта: USD

7.13

-1.08 (-13.15%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

7.36

+0.23 (3.29%)

После закрытия: Jun 26, 2026, 7:59 PM EDT

08.06.2026

Stock Picks From Seeking Alpha's May 2026 New Analysts

Seeking Alpha welcomed 24 new analysts in May 2026. This article introduces them and showcases some of their top picks. Spotlighted ideas include bullish theses on Google, Manulife, and Unicycive Therapeutics, and a neutral-rated analysis on Agree Realty. We recently welcomed Nataliia Gurinenko, from IVCompass, as part of our syndicated content coverage. Nataliia will use options flow analysis to interpret market positioning and sentiment, with a focus on digital assets.

21.05.2026

Unicycive Therapeutics: A Catalyst Play With Real Fundamental Upside

Unicycive Therapeutics is valued at $8/share, with $2/share in cash and the pipeline—primarily OLC—valued at $6/share. OLC targets hyperphosphatemia by reducing pill burden, aiming for improved patient adherence, with a PDUFA date set for June 29, 2026. Key risks include payer acceptance of premium pricing, patent term uncertainty, and lack of outcomes data supporting improved adherence.

12.05.2026

Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

MOUNTAIN VIEW, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the first quarter ended March 31, 2026, and provided a business update.

16.04.2026

Unicycive Therapeutics, Inc. (UNCY) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

09.04.2026

Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm

NEW YORK, April 9, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Unicycive Therapeutics caused the company to misrepresent or fail to disclose that: (i) Unicycive's readiness and ability to satisfy the FDA's manufacturing compliance requirements was overstated; (ii) the OLC NDA's regulatory prospects were likewise overstated; and (iii) as a result, public statements were materially false and misleading at all relevant times.

09.04.2026

Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

LOS ALTOS, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will present at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026, at 3:45 p.m. ET.

30.03.2026

Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

LOS ALTOS, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the full year ended December 31, 2025, and provided a business update.

Видео

No Data

There is no data to display

Пресс-релизы

12.05.2026

Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

09.04.2026

Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm

30.03.2026

Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

06.03.2026

Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm

New York, New York--(Newsfile Corp. - March 6, 2026) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Unicycive Therapeutics caused the company to misrepresent or fail to disclose that: (i) Unicycive's readiness and ability to satisfy the FDA's manufacturing compliance requirements was overstated; (ii) the OLC NDA's regulatory prospects were likewise overstated; and (iii) as a result, public statements were materially false and misleading at all relevant times.

Unicycive Therapeutics, Inc. (UNCY)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Unicycive Therapeutics, Inc. (UNCY)

Stock Picks From Seeking Alpha's May 2026 New Analysts

Unicycive Therapeutics: A Catalyst Play With Real Fundamental Upside

Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

Unicycive Therapeutics, Inc. (UNCY) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm

Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

Видео

No Data

Пресс-релизы

Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm

Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm

Stock Picks From Seeking Alpha's May 2026 New Analysts

Unicycive Therapeutics: A Catalyst Play With Real Fundamental Upside

Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

Unicycive Therapeutics, Inc. (UNCY) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm

Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

Видео

No Data

Пресс-релизы

Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm

Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm

Search stocks

Unicycive Therapeutics, Inc. (UNCY)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Unicycive Therapeutics, Inc. (UNCY)

Stock Picks From Seeking Alpha's May 2026 New Analysts

Unicycive Therapeutics: A Catalyst Play With Real Fundamental Upside

Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

Unicycive Therapeutics, Inc. (UNCY) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm

Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

Видео

No Data

Пресс-релизы

Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm

Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm

Stock Picks From Seeking Alpha's May 2026 New Analysts

Unicycive Therapeutics: A Catalyst Play With Real Fundamental Upside

Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

Unicycive Therapeutics, Inc. (UNCY) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm

Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

Видео

No Data

Пресс-релизы

Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm

Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm